Oral trans-mucosal administration of ticagrelor: is this really the future?
Fabiana
F
Rollini
Francesco
F
Franchi
Dominick J. Angiolillo, MD, PhD, University of Florida College of Medicine-Jacksonville, 655 West 8th Street, Jacksonville, FL 32209, USA, Tel.: +1 904 244 3933, Fax: +1 904 244 3102, E-mail: dominick.angiolillo@jax.ufl.edu.
Dominick J
DJ
Angiolillo
D000241:Adenosine / Q000031:analogs & derivatives; D058956:Administration, Mucosal; D000284:Administration, Oral; D006801:Humans; D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor
D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000241:Adenosine